[Histological picture of angular alopecia in women].

W. Kostanecki,M. Janiszewska,L. Fabjańska,W. Mazurkiewicz,A. Górkiewicz,A. Kozłowska,E. Miedzińska

Abstract:

What problem does this paper attempt to address?

Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method

Ling Ye,Zeying Feng,Longjian Huang,Chengjun Guo,Xiong Wu,Li He,Wei Tan,Yi Wang,Xuehong Wu,Biwen Hu,Tong Li,Guoping Yang,Guo Chengxian,Qingnan He

DOI: https://doi.org/10.3389/fphar.2021.790108

IF: 5.6

2021-12-20

Frontiers in Pharmacology

Abstract:Purpose: Drug-induced liver injury (DILI) is a common adverse reaction in the clinic; however, there are relatively few reports of DILI in critically ill newborns and children. Making use of the Pediatric Intensive Care database (PIC), this study identifies which drugs are related to DILI in neonates and children in China. Methods: Using the PIC, we screened for patients whose liver was suspected of being injured by drugs during hospitalization. The medicine they used was then assessed by the Roussel Uclaf Causality Assessment Method (RUCAM). At the same time, we also collated drug combinations that may affect CYP (Cytochrome P) enzyme metabolism, which may cause DILI. Results: A total of 13,449 patients were assessed, of whom 77 newborns and 261 children were finally included. The main type of liver injury in neonates was mixed (83.1%), while the hepatic injury types of children were mostly distributed between hepatocellular (59.4%) and cholestatic (28.4%). In terms of the RUCAM assessment, the drugs that were most considered to cause or be associated with hepatic injury in newborns were medium and long chain fat emulsions (17%), sodium glycerophosphate (12%), and meropenem (9%); while omeprazole (11%), methylprednisolone sodium succinate (10%), and meropenem (8%) were the primary culprits of DILI in children. Drug combinations frequently seen in neonates that may affect CYP enzyme metabolism are omeprazole + budesonide (16.9%), dexamethasone + midazolam (10.4%), and midazolam + sildenafil (10.4%). In children, the commonly used drug combinations are fentanyl + midazolam (20.7%), ibuprofen + furosemide (18.4%), and diazepam + omeprazole (15.3%). Conclusions: In this study, medium and long chain fat emulsions and sodium glycerophosphate have been strongly associated with DILI in newborns, while omeprazole and methylprednisolone sodium succinate play an important role in the DILI of children. Also, attention should be paid to the effect on CYP enzymes when using multiple drugs at the same time. In future DILI cases, it is advisable to use the latest RUCAM for prospective study design so that complete case data and high RUCAM scores can be collected.

pharmacology & pharmacy
Potential drug–drug interactions analysis in Polish pediatric pneumonology units, including cystic fibrosis patients

Arkadiusz Adamiszak,Julia Drobińska,Irena Wojsyk‐Banaszak,Edmund Grześkowiak,Agnieszka Bienert

DOI: https://doi.org/10.1002/jcph.2478

2024-06-04

The Journal of Clinical Pharmacology

Abstract:The lack of data on drug–drug interactions in pediatrics represents a relevant problem in making appropriate therapeutic decisions. Our study aimed to investigate the incidence and risk factors for potential drug–drug interactions (pDDIs) in pediatric pneumonology units, including cystic fibrosis patients. We performed a 6‐month prospective observational study during which clinical pharmacists, using the Lexicomp Drug Interactions checker, screened medical records to identify pDDIs. Spearman's rank coefficient, logistic regression, and the Mann–Whitney U test were used to identify correlations, analyze risk factors for pDDIs, and compare cystic fibrosis patients with the rest, respectively. Recommendations were provided for the D and X pDDIs categories. Within the 218 patients, 428 pDDIs were identified, out of which 237 were classified as clinically significant. Almost 60% of patients were exposed to at least one relevant interaction. The number of pDDIs correlated with the number of; drugs (rs = 0.53, P < .001), hospitalization length (rs = 0.20, P < .01), and off‐label medicines (rs = 0.25, P < .001). According to the multivariate analysis, at least 6 administered medications (OR = 4.15; 95% CI = 2.21–7.78), 4 days of hospitalization (OR = 6.41; 95% CI = 2.29–17.97), and off‐label therapy (OR = 3.37; 95% CI = 1.69–6.70) were the risk factor for pDDIs. Despite significant differences in the number of medications taken, comorbidities, and off‐label drugs, cystic fibrosis patients were not more exposed to pDDI. Given the lack of data on pDDIs in the pediatric population, the need for close cooperation between clinicians and clinical pharmacists to improve the safety and efficacy of pharmacotherapy is highlighted.

pharmacology & pharmacy
Psychometric evaluation of the Nurses Observation Scale for Inpatient Evaluation in the Netherlands

A. Hafkenscheid

DOI: https://doi.org/10.1111/j.1600-0447.1991.tb05510.x

1991-01-01

Acta Psychiatrica Scandinavica

Abstract:The interrater reliability, temporal stability and factorial, convergent, discriminant and predictive validity of the Nurses Observation Scale for Inpatient Evaluation (NOSIE‐30) were investigated in a heterogeneous group of psychiatric inpatients in the Netherlands (n= 179). Data in support of the scale's dimensional structure (recoverability of Anglo‐American subscale structure in this Dutch sample and distinctiveness of subscales), discriminatory power and convergent validity are presented. Interrater reliability was satisfactory at global scale level. However, 3 subscales (irritability, psychosis and depression) were found to lack interrater reliability. Although temporal stability coefficients were high, large score changes are presupposed to show that pre‐ versus posttherapy differences are attributable to real change rather than error. NOSIE‐30 had limited predictive value.
Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients

Jiali Zhang,Danyi Ma,Meng Chen,Yanting Hu,Xveying Chen,Jingyu Chen,Man Huang,Haibin Dai

DOI: https://doi.org/10.3389/fphar.2024.1308260

IF: 5.6

2024-02-07

Frontiers in Pharmacology

Abstract:Background: Drug-drug interactions (DDIs) are a major but preventable cause of adverse drug reactions. There is insufficient information regarding DDIs in lung transplant recipients. Objective: This study aimed to determine the prevalence of potential DDIs (pDDIs) in intensive care unit (ICU) lung transplant recipients, identify the real DDIs and the most frequently implicated medications in this vulnerable population, and determine the risk factors associated with pDDIs. Methods: This retrospective cross-sectional study included lung transplant recipients from January 2018 to December 2021. Pertinent information was retrieved from medical records. All prescribed medications were screened for pDDIs using the Lexicomp ® drug interaction software. According to this interaction software, pDDIs were classified as C, D, or X (C = monitor therapy, D = consider therapy modification, X = avoid combination). The Drug Interaction Probability Scale was used to determine the causation of DDIs. All statistical analysis was performed in SPSS version 26.0. Results: 114 patients were qualified for pDDI analysis, and total pDDIs were 4051. The most common type of pDDIs was category C (3323; 82.0%), followed by D (653; 16.1%) and X (75; 1.9%). Voriconazole and posaconazole were the antifungal medicine with the most genuine DDIs. Mean tacrolimus concentration/dose (Tac C/D) before or after co-therapy was considerably lower than the Tac C/D during voriconazole or posaconazole co-therapy ( p < 0.001, p = 0.027). Real DDIs caused adverse drug events (ADEs) in 20 patients. Multivariable logistic regression analyses found the number of drugs per patient (OR, 1.095; 95% CI, 1.048–1.145; p < 0.001) and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score (OR, 1.097; 95% CI, 1.021–1.179; p = 0.012) as independent risk factors predicting category X pDDIs. Conclusion: This study revealed a high incidence of both potential and real DDIs in ICU lung transplant recipients. Immunosuppressive drugs administered with azole had a high risk of causing clinically significant interactions. The number of co-administered drugs and APACHE II score were associated with an increased risk of category × drug interactions. Close monitoring of clinical and laboratory parameters is essential for ensuring successful lung transplantation and preventing adverse drug events associated with DDIs.

pharmacology & pharmacy
Major Drug–Drug Interaction Exposure Among Medicaid-Insured Children in the Outpatient Setting

Kathryn E Kyler,Matt Hall,James W Antoon,Jennifer Goldman,Samir S Shah,Sonya Tang Girdwood,Derek J Williams,James A Feinstein,Kathryn E. Kyler,James W. Antoon,Samir S. Shah,Derek J. Williams,James A. Feinstein

DOI: https://doi.org/10.1542/peds.2023-063506

2024-01-01

PEDIATRICS

Abstract:BACKGROUND AND OBJECTIVES Drug–drug interactions (DDIs) can cause adverse drug events, but little is known about DDI exposure in children in the outpatient setting. This study aimed to determine the prevalence of major DDI exposure and factors associated with higher DDI exposure rates among children in an outpatient setting. METHODS We performed a cross-sectional study of children aged 0 to 18 years with ≥1 ambulatory encounter, and ≥2 dispensed outpatient prescriptions study using the 2019 Marketscan Medicaid database. DDIs (exposure to a major DDI for ≥1 day) and the adverse physiologic effects of each DDI were identified using DrugBank’s interaction database. Primary outcomes included the prevalence and rate of major DDI exposure. We used logistic regression to assess patient characteristics associated with DDI exposure. We examined the rate of DDI exposures per 100 children by adverse physiologic effects category, and organ-level effects (eg, heart rate-corrected QT interval prolongation). RESULTS Of 781 019 children with ≥2 medication exposures, 21.4% experienced ≥1 major DDI exposure. The odds of DDI exposure increased with age and with medical and mental health complexity. Frequently implicated drugs included: Clonidine, psychiatric medications, and asthma medications. The highest adverse physiologic effect exposure rate per 100 children included: Increased drug concentrations (14.6), central nervous system depression (13.6), and heart rate-corrected QT interval prolongation (9.9). CONCLUSIONS One in 5 Medicaid-insured children with ≥2 prescription medications were exposed to major DDIs annually, with higher exposures in those with medical or mental health complexity. DDI exposure places children at risk for negative health outcomes and adverse drug events, especially in the harder-to-monitor outpatient setting.

pediatrics
Evaluation of Potentially Inappropriate Prescription and Drug-Drug Interactions in the Critically Sick Elderly Patients in China

Xiaohu Yang,Orgah John Owoicho,Fengjia Zhu,Wei Liu,Yihua Yu

DOI: https://doi.org/10.21203/rs.3.rs-888771/v1

2021-09-10

Abstract:Abstract Background There is ongoing debate about the incidence and relationships of potentially inappropriate prescriptions and drug-drug interactions (DDIs) in elderly patients in China. Objective This study aims to evaluate the prevalence of potentially inappropriate medications (PIMs) and DDIs in elderly patients in an intensive care unit (ICU). Methods A total of 547 patients aged ≥65 years from the 30-bed ICU in a 3A (Class Three/Grade A) hospital in China over a 1-year period were included. The participant statistics and drugs prescribed were collected by the Hospital Information System (HIS). The study was limited to drugs ordered at and during ICU hospitalization. The drug list of every patient was reviewed to identify PIMs based on the 2012 Beers criteria, and the drugs implicated in PIMs were classified at five levels according to World Health Organization Anatomical Therapeutic Chemical classification. Results In total, 94.3% of the patients had prescriptions for ≥10 drugs, and 61.4% of the patients were prescribed at least one PIM. DDIs were identified in 95.6% of the medication profiles evaluated. Conclusions The results of this study conducted in an ICU setting that assessed the incidence and relationships of PIMs and pDDIs in elderly patients in China, providing baseline information and quantifying drug-related problems among critically ill elderly patients receiving PIMs. It is of clinical importance that better information must be provided to physicians and intensive care specialists regarding the risks and benefits of drug therapy, and patient compliance and inappropriate and unnecessary prescriptions must be addressed.
Prevalence of Potential Drug-Drug Interactions among Intensive Care Unit Patients Receiving Linezolid: a Cross-Sectional Study.

H. -Y. Jiang,L. -Y. Yu,X. Wang,Z. -W. Yu,Y. -H. Zhao

DOI: https://doi.org/10.26355/eurrev_202310_33967

2023-01-01

Abstract:OBJECTIVE:Linezolid is commonly used in intensive care units (ICU) but has the potential to interact with other drugs. This study aimed to evaluate the prevalence of potential drug-drug interactions in ICU patients receiving linezolid.PATIENTS AND METHODS:Data of ICU patients receiving linezolid were extracted and included in the Hospital Prescription Analysis Program of China, and the risk of potential drug-drug interactions between concomitant drugs and linezolid was evaluated using the Lexicomp database.RESULTS:A total of 3,712 ICU patients from 59 hospitals were included in the analysis, and patients received an average of 17 concomitant drugs. A total of 67.9% of patients had potential drug-drug interactions. Patients receiving concomitant drugs with risk ratings of "X", "D", and "C" categories were 20.8%, 30.4%, and 35.1%, respectively. Opioids were the most frequently prescribed drug class with drug-drug interactions (DDIs) in the "X" category, whereas butorphanol, metoclopramide, and sufentanil were the most contraindicated concomitant drugs.CONCLUSIONS:ICU patients receiving linezolid have a high prevalence of potential drug-drug interactions, and efforts should be made to better recognize and manage this risk.
Evaluation of Clinical Impact of Pharmacogenomics Knowledge Involved in CPIC Guidelines on Chinese Pediatric Patients

Weifeng Qin,Zhenglin Du,Jingfa Xiao,Huilong Duan,Qiang Shu,Haomin Li

DOI: https://doi.org/10.2217/pgs-2019-0153

2020-01-01

Pharmacogenomics

Abstract:Aim: To evaluate the clinical benefits of implementing pharmacogenomics testing for Chinese pediatric patients. Materials & methods : Based on the drug–gene interactions involved in the Clinical Pharmacogenetics Implementation Consortium guidelines, whole-genome sequencing data from the Chinese Academy of Sciences Precision Medicine Initiative project and the medication data of pediatric patients from a children's hospital, the prevalence of the Chinese population with actionable pharmacogenomic variants was calculated, the prescribing pattern for pediatric patients was analyzed. Results: 37.0% of the drugs involved in the Clinical Pharmacogenetics Implementation Consortium guidelines were used by Chinese pediatric patients, 8.91% inpatients and 0.89% outpatients received at least one pharmacogenomics medication, 1.24% (4803) inpatients and 0.16% (2940) outpatients were estimated to be at high risk of pharmacogenomic-related adverse therapeutic outcomes. Conclusion: Implementing pharmacogenomics testing can improve therapeutic outcomes for many Chinese pediatric patients.
Optimization of Cutting Process of Medium Density Fibreboards by the Abrasive Water-Jet

Š. Barcík,M. Kvietková,R. Kminiak,P. Alac

DOI: https://doi.org/10.5552/DRIND.2011.1113

Abstract:This paper deals with the process of MDF cutting by the abrasive water-jet (WJC) and shows how is kerf width infl uenced by process parameters. It presents the results of monitoring the kerf width related to technical and technological parameters, material parameters and cutting method. At the end of this paper, there is a detailed presentation of the possibilities of impacting kerf width by the change of the above mentioned parameters of the cutting process.
Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

Daniel C. Malone,Jacob Abarca,Philip D. Hansten,Amy J. Grizzle,Edward P. Armstrong,Robin C. Van Bergen,Babette S. Duncan-Edgar,Steven L. Solomon,Richard B. Lipton

DOI: https://doi.org/10.1016/j.amjopharm.2005.05.001

2005-06-01

The American Journal of Geriatric Pharmacotherapy

Abstract:Objective:To develop a list of clinically important drug-drug interactions (DDIs) likely to be encountered in community and ambulatory pharmacy settings and detected by a computerized pharmacy system.Design:Cross-sectional, one-time evaluation.Setting:United States in fall 2001.Participants:An expert panel comprising two physicians, two clinical pharmacists, and an expert on DDIs.Interventions:Systematic review of drug interaction compendia and published literature, ratings (on a 1 to 10 scale) of various clinical aspects of DDIs (e.g., clinical importance, quality and quantity of evidence, causal relationship, risk of morbidity and mortality), and a modified Delphi consensus-building process.Main Outcome Measure:Panelists' opinions about clinical importance of DDIs.Results:The expert panel considered 56 DDIs. Of these, 28 had a mean clinical importance score of 8.0 or more. The ratings for clinical importance ranged from 3.2 to 9.6, with a mean ± SD of 7.5 ± 1.5 across the combinations examined. The mean score for the quality of literature suggesting the interaction exists ranged from 1.0 to 9.6, with a mean ± SD of 5.8 ± 2.5. In terms of substantiation of the interactions evaluated, the mean ± SD rating was 6.3 ± 2.2, with a range from 1.4 to 9.2. Through the modified Delphi process, the panel determined that 25 interactions were clinically important.Conclusion:Using an expert panel and a standard evaluation tool, 25 clinically important drug interactions that are likely to occur in the community and ambulatory pharmacy settings were identified. Pharmacists should take steps to prevent patients from receiving these interacting medications, and computer software vendors should focus interaction alerts on these and similarly important DDIs.

English Else
Prevalence and comparative analysis of potential drug-drug interactions among hospitalized patients at a tertiary care cardiac institute in Pakistan: Findings from a single centre

Ahmad Ullah Humza,Muhammad Asad Akbar,Muhammad Asad Bilal Awan,Jibran Bin Yousuf,Khalid Khan,Ali Ammar

Abstract:Hospitalized post-operative cardiovascular disease (CVD) patients are often subject to polypharmacy, increasing the risk of potential drug-drug interactions (pDDIs). This observational study assessed 384 post-operative CVD patients for pDDIs using Micromedex Drug-Int® and Lexicomp Interact®. Prevalence, severity, onset and documentation of pDDIs were analyzed using SPSS 23.0, with logistic regression identifying factors associated with at least two major pDDIs or two pDDIs categorized as X, D, or C. Micromedex Drug-Int® revealed a median of 6.23 pDDIs per patient, with 98.7% of patients having ≥1 pDDIs. Of 2,389 pDDIs, 64.1% were major. Lexicomp Interact® data showed a median of 7.15 pDDIs per patient, with 99.2% of patients having ≥1 pDDIs. Class C interactions were the most frequent (62.1%), followed by Classes B, D and X. Additionally, the study identified unique pDDIs from Lexicomp, including Ipratropium-Orphenadrine and Furosemide-Levosulpiride, not listed in Micromedex. The findings highlight the high prevalence of pDDIs in this population, emphasizing the need for regular monitoring. Using pDDI screening tools, clinical pharmacists can be crucial in mitigating these risks, particularly in high-risk patients.
Drug-induced kidney injury in Chinese critically ill pediatric patients

Biwen Hu,Ling Ye,Tong Li,Zeying Feng,Longjian Huang,Chengjun Guo,Li He,Wei Tan,Guoping Yang,Zhiling Li,Chengxian Guo

DOI: https://doi.org/10.3389/fphar.2022.993923

IF: 5.6

2022-09-26

Frontiers in Pharmacology

Abstract:Background: Drug-induced acute kidney injury (DIKI) is a common adverse drug reaction event but is less known in pediatric patients. The study explored the DIKI in Chinese pediatric patients using the Pediatric Intensive Care database (PIC). Method: We screened pediatric patients with acute kidney injury (AKI) using the KDIGO criteria from the PIC and then assessed the relationship between their drugs and DIKI using the Naranjo scale. For the fifteen frequently used DIKI-suspected drugs, we divided patients into drug-exposed and non-exposed groups, using the outcome of whether DIKI was presented or not. Propensity score matching (PSM) was used to control for the effects of four confounders, age, gender, length of hospital stay, and major diagnosis. Unconditional logistic regression was used to identify statistically significant differences between the two groups. Results: A total of 238 drugs were used 1,863 times by the 81 patients with DIKI during their hospital stay. After screening the Naranjo scale to identify the top 15 suspected DIKI drugs with a high frequency of use, we found that furosemide injection ( p = 0.001), midazolam injection ( p = 0.001), 20% albumin prepared from human plasma injection ( p = 0.004), fentanyl citrate injection ( p = 0.001), compound glycyrrhizin injection ( p = 0.026), vancomycin hydrochloride for intravenous ( p = 0.010), and milrinone lactate injection ( p = 0.009) were associated with DIKI. Conclusion: In critically ill pediatric patients, DIKI is more likely to occur after using furosemide injection, midazolam injection, 20% albumin prepared from human plasma injection, fentanyl citrate injection, compound glycyrrhizin injection, vancomycin hydrochloride for intravenous, milrinone lactate injection.

pharmacology & pharmacy
When Free 'Drug-Interaction Checker Mobile Apps' Ensure Interaction Free Medications for ICU Patients in Resource Limited Setups

Jahidul Hasan,Raihan Rabbani,Sitesh C. Bachar,Md. Jahidul Hasan

DOI: https://doi.org/10.2139/ssrn.3362464

2019-01-01

SSRN Electronic Journal

Abstract:Polypharmacy prescriptions increase the risk of drug-drug interactions (DIs) including potential drug-drug interactions (PDI) leading to alteration of drugs' therapeutic responses and occurrence of adverse drug reactions (ADRs). Critical care pharmacists (CCP) are the key responsible persons for monitoring DIs and PDIs, and drug-interaction checker mobile apps (DICMA) are the most useful tool. The main objective of this study was to evaluate the outcomes of CCP interventions in monitoring the DIs/PDIs in ICU-patients of a resource limited setup by using free DICMA. This retrospective study was conducted in a hospital in Dhaka, Bangladesh. Without having any paid DICMA, CCP of that ICU used the free DICMA: 'Medscape' and 'Epocrates' to check DIs frequently in every prescription, CCP suggested to doctors and prescriptions were modified, accordingly. Those suggestions were collected from the hospital data archive and the satisfaction level of CCP to DICMA was measured. CCP worked on 2,967 critical patients, 11,128 DIs were detected, 3,932 PDIs were identified and suggested to doctors. In every patient, 1.77 (on average) PDIs were calculated. Prescriptions containing 6 to 10 medications and above 10 medications, the number of available DIs were 3.28 and 7.53, respectively; and the number of PDIs were 1.42 and 4.7, respectively. Doctors accepted 95.85% of total PDIs suggestions (n= 3,932) and 30.41% of those PDIs suggestions yielded immediate positive responses in patients. The satisfaction level of CCP in using free DICMA was 4 (on a scale of 5). Most of the resource limited setups are unable to provide a paid DICMA to its CCP for monitoring DIs. Free DICMA can be an alternative solution for CCP to safe the critical patients from serious DIs, PDIs and ADRs through frequently screening the prescriptions, easily and cost-effectively.Funding Statement: The authors state: "No external funding source for this study."Declaration of Interests: The authors declare: "No conflicts of interest."Ethics Approval Statement: The ethical approval for this study was taken on March, 2017 from the hospital ethical committee.
A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Gang Yu,Xian Zeng,Shaoqing Ni,Zheng Jia,Weihong Chen,Xudong Lu,Jiye An,Huilong Duan,Qiang Shu,Haomin Li

DOI: https://doi.org/10.1186/s12874-020-0902-x

2020-01-01

BMC Medical Research Methodology

Abstract:Background Drug safety in children is a major concern; however, there is still a lack of methods for quantitatively measuring, let alone to improving, drug safety in children under different clinical conditions. To assess pediatric drug safety under different clinical conditions, a computational method based on Electronic Medical Record (EMR) datasets was proposed. Methods In this study, a computational method was designed to extract the significant drug-diagnosis associations (based on a Bonferroni-adjusted hypergeometric P-value < 0.05) among drug and diagnosis co-occurrence in EMR datasets. This allows for differences between pediatric and adult drug use to be compared based on different EMR datasets. The drug-diagnosis associations were further used to generate drug clusters under specific clinical conditions using unsupervised clustering. A 5-layer quantitative pediatric drug safety level was proposed based on the drug safety statement of the pediatric labeling of each drug. Therefore, the drug safety levels under different pediatric clinical conditions were calculated. Two EMR datasets from a 1900-bed children's hospital and a 2000-bed general hospital were used to test this method. Results The comparison between the children's hospital and the general hospital showed unique features of pediatric drug use and identified the drug treatment gap between children and adults. In total, 591 drugs were used in the children's hospital; 18 drug clusters that were associated with certain clinical conditions were generated based on our method; and the quantitative drug safety levels of each drug cluster (under different clinical conditions) were calculated, analyzed, and visualized. Conclusion With this method, quantitative drug safety levels under certain clinical conditions in pediatric patients can be evaluated and compared. If there are longitudinal data, improvements can also be measured. This method has the potential to be used in many population-level, health data-based drug safety studies.
Prevalence and predictors of potential drug–drug interactions in patients of internal medicine wards of a tertiary care hospital in India

Yugandhar Bethi,Deepak Gopal Shewade,Tarun Kumar Dutta,Batmanabane Gitanjali

DOI: https://doi.org/10.1136/ejhpharm-2017-001272

2017-07-19

European Journal of Hospital Pharmacy

Abstract:BACKGROUND: Drug-drug interactions are a major source of adverse drug events (ADEs). Polypharmacy, age and the number of comorbid conditions are important predictors of adverse drug interactions. ADEs account for up to 5% of hospital admissions per year and an increase in the length of hospital stay.OBJECTIVE: To find the prevalence and predictors of potential drug-drug interactions (pDDIs) in patients admitted to the wards of an internal medicine department of a tertiary care hospital.METHOD: Patients admitted to internal medicine wards with prescriptions having more than one drug were selected. Demographic details including age, gender, number of comorbid conditions, number of drugs prescribed and the disease for which the patient was admitted were recorded in a case record form. Interactions were checked using Micromedex DrugReax software.RESULTS: A total of 939 patients were recruited for this study based on inclusion criteria. 433 prescriptions (46%) had one or more pDDIs, with a range of 1-13 drug interactions per prescription. A total of 1395 drug interactions were found, with 866 moderate drug interactions (62%), 435 major interactions (31.1%) and 89 minor interactions (6.3%). During the study period only three contraindicated drug combinations (0.2%) were recorded. A significant association (p<0.01) was found between the number of pDDIs and predictors, age and number of drugs.CONCLUSION: A total of 433 prescriptions (46%) had one or more pDDIs. Older patients and those prescribed >6 drugs are at major risk for occurrence of pDDIs. Moderate severity interactions were the highest number followed by major severity interactions.

pharmacology & pharmacy
Epidemiology of potential drug- drug interactions in hospitalized patients with type 2 diabetes mellitus in China: a retrospective study

Weifang Ren,Yujuan Liu,Huaqiao Jiang,Xiaoqun Lv,Ning Zhang

DOI: https://doi.org/10.3389/fendo.2024.1387242

IF: 6.055

2024-06-25

Frontiers in Endocrinology

Abstract:Background: Combination therapy was associated with an increased risk of drug- drug interactions (DDIs) in patients with type 2 diabetes mellitus (T2DM). The present study aimed to investigate the epidemiology of potential DDIs (pDDIs), including potential chemical drug-drug interactions (pCDIs) and potential herb-drug interactions (pHDIs), and classify the influencing factors of pDDIs in these patients. Methods: A retrospective study of the epidemiology of pDDIs among T2DM hospitalized patients older than 18 years and treated with at least two drugs during hospitalization was conducted over a 12-month period in 2019. PDDIs were identified with C (monitor therapy), D (consider therapy modification), and X (avoid combination) risk ratings. Binary logistic regression was used to analyze the risk factors of pDDIs. Results: A total of 6796 pDDIs were identified from 737 T2DM hospitalized patients during hospitalization, with 0.87% classified as X risk rating, 13.39% as D risk rating. Additionally, 1753 pDDIs were identified after discharge, with 0.11% as X and 25.73% as D risk rating. The drug-drug association networks showed that the majority of pCDIs were associated with cardiovascular system drugs. Chlorphenamine-potassium chloride and danshen-warfarin were the most prevalent interacting pairs of pCDIs and pHDIs with X rating during hospitalization. Multivariate analysis indicated that the likelihood of developing over 4 pDDIs was significantly higher among T2DM patients who had received over 8 medications. The presence of pDDIs after discharge was strongly associated with the complications of T2DM and the number of discharge medications. Conclusions: T2DM patients were frequently exposed to pDDIs, including pCDIs and pHDIs, both during hospitalization and after discharge. Multi-drug combination was the primary risk factor for pDDIs. Strategies such as enhancing the monitoring and warning for pDDIs, increasing clinical pharmacological experience, as well as developing universally applicable clinical guidelines for pDDIs may be beneficial in reducing the incidence of potentially harmful drug-combinations.

endocrinology & metabolism
Drug Induced Liver Injury in Children: A Nationwide Cohort Study from China

Rongtao Lai,Xinjie Li,Jie Zhang,Jun Chen,Changqing Yang,Wen Xie,Yuecheng Yu,Xiaoyan Guo,Xinrong Zhang,Guoliang Lu,Xi'an Han,Qing Xie,Chengwei Chen,Tao Shen,Yimin Mao

DOI: https://doi.org/10.1016/j.jhepr.2024.101102

IF: 9.917

2024-01-01

JHEP Reports

Abstract:Background & Aims: Currently, there is limited knowledge on the clinical profile of drug-induced liver injury (DILI) in Chinese children. We aimed to assess the clinical characteristics, suspected drugs, and outcomes associated with pediatric DILI in China. Methods: This nationwide, multicenter, retrospective study, conducted between 2012 and 2014, analyzed 25,927 cases of suspected DILI at 308 medical centers using the inpatient medical register system. Utilizing the Roussel Uclaf causality assessment method score, only patients with scores ≥6 or diagnosed with DILI by three experts after scoring <6 were included in the analysis. Among them, 460 cases met the EASL biochemical criteria. The study categorized children into three age groups: toddlers (≥30 days to <6 years old), school-age children (6 to <12 years old), and adolescents (12 to <18 years old). Results: Hepatocellular injury was the predominant clinical classification, accounting for 63% of cases, with 34% of these cases meeting Hy's law criteria. Adolescents comprised the majority of children with moderate/severe DILI (65%). Similarly, adolescents faced a significantly higher risk of severe liver injury compared to younger children (adjusted odd ratios 4.75, p = 0.002). The top three most frequently prescribed drug classes across all age groups were antineoplastic agents (25.9%), antimicrobials (21.5%), and traditional Chinese medicine (13.7%). For adolescents, the most commonly suspected drugs were antitubercular drugs (22%) and traditional Chinese medicine (23%). Conclusion: Adolescents are at a greater risk of severe and potentially fatal liver injury compared to younger children. Recognizing the risk of pediatric DILI is crucial for ensuring safe medical practices. Impact and implications:: Drug-induced liver injury, a poorly understood yet serious cause of pediatric liver disease, encompasses a spectrum of clinical presentations, ranging from asymptomatic liver enzyme elevation to acute liver failure. This retrospective study, utilizing a large Chinese cohort of pediatric liver injury cases from 308 centers nationwide, characterized the major clinical patterns and suspected drugs in detail, revealing that adolescents are at a greater risk of severe liver injury compared to younger children. Vigilant care and careful surveillance of at-risk pediatric patients are crucial for physicians, researchers, patients, caregivers, and policymakers. Additional multicenter prospective studies are needed to evaluate the risk of hepatotoxicity in outpatients and hospitalized pediatric patients.
DDInter: an online drug–drug interaction database towards improving clinical decision-making and patient safety

Guoli Xiong,Zhijiang Yang,Jiacai Yi,Ningning Wang,Lei Wang,Huimin Zhu,Chengkun Wu,Aiping Lu,Xiang Chen,Shao Liu,Tingjun Hou,Dongsheng Cao

DOI: https://doi.org/10.1093/nar/gkab880

IF: 14.9

2021-10-11

Nucleic Acids Research

Abstract:Abstract Drug-drug interaction (DDI) can trigger many adverse effects in patients and has emerged as a threat to medicine and public health. Despite the continuous information accumulation of clinically significant DDIs, there are few open-access knowledge systems dedicated to the curation of DDI associations. To facilitate the clinicians to screen for dangerous drug combinations and improve health systems, we present DDInter, a curated DDI database with comprehensive data, practical medication guidance, intuitive function interface, and powerful visualization to the scientific community. Currently, DDInter contains about 0.24M DDI associations connecting 1833 approved drugs (1972 entities). Each drug is annotated with basic chemical and pharmacological information and its interaction network. For DDI associations, abundant and professional annotations are provided, including severity, mechanism description, strategies for managing potential side effects, alternative medications, etc. The drug entities and interaction entities are efficiently cross-linked. In addition to basic query and browsing, the prescription checking function is developed to facilitate clinicians to decide whether drugs combinations can be used safely. It can also be used for informatics-based DDI investigation and evaluation of other prediction frameworks. We hope that DDInter will prove useful in improving clinical decision-making and patient safety. DDInter is freely available, without registration, at http://ddinter.scbdd.com/.

biochemistry & molecular biology
Potential drug-drug interactions and associated factors among hospitalized pediatric patients in Adigrat general hospital, Tigrai, north Ethiopia: a retrospective cross-sectional study

Gebretekle Gebremichael Hailesilase,Abrahaley Mulu Kidane,Haylay Araya Gebrezgabiher

DOI: https://doi.org/10.1186/s12887-024-05128-9

2024-10-13

BMC Pediatrics

Abstract:Drug-drug interactions (DDIs) are associated with increased or decreased adverse effects and decreased or decreased therapeutic effects. Hospitalized pediatric patients are exposed to a number of potential DDIs (pDDIs). There are limited studies on pDDIs among pediatric patients in Ethiopia. This study was aimed to evaluate the pDDIs and associated factors among hospitalized pediatric patients in Adigrat general hospital, Tigrai, northern Ethiopia.

pediatrics
Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital

Virendra K Patel,Leelavathi D Acharya,Thiyagu Rajakannan,Mallayasamy Surulivelrajan,Vasudeva Guddattu,Ramachandran Padmakumar

DOI: https://doi.org/10.4066/AMJ.2011.450

Abstract:Background: The potential drug-drug interaction (pDDI) increases as the number of concomitant medications increases. Patients with cardiovascular disorders are at higher risk for drug- drug interactions because of the types and number of drugs they receive. While drug interactions are reported to be common, there is no published report of the prevalence of such interactions among Indian cardiac patients. The aim of the present study was to identify the pattern of pDDI and document any observed interaction. It was also planned to evaluate the demography of patients and correlate it with the drug-drug interactions. Method: A prospective observational study from Oct 2007 to Apr 2008 was carried out in 'cardiology department' of a hospital in South India. Those patients who were taking at least two drugs and had a hospital stay of at least 48 hours were included in the study. The medications of the patients were analyzed for possible interactions. Factors associated with pDDI were studied. The actual interactions that were observed during the hospital stay in the study subjects were documented. Results: A total of 812 patients were included in the study. 388 pDDIs were identified among 249 patients. The incidence of pDDI was 30.67%. The most common potential interactions were between aspirin & heparin (29.38%), and clopidogrel & heparin (7.21%). Drug classes most commonly involved were antiplatelets, anticoagulants and diuretics. Majority of interactions were of moderate severity, delayed onset, and pharmacodynamic in nature. Total 68 actual interactions were observed in the observed cases. Conclusion: The present study identified pDDIs and also documented interactions in cardiovascular patients. Factors which had correlation with adverse drug interactions were identified. This study highlights the need for screening prescriptions of cardiovascular patients for pDDIs and proactive monitoring of patients who have identified risk factors; this helps in detection and prevention of possible adverse drug interactions.

[Histological picture of angular alopecia in women].

Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method

Potential drug–drug interactions analysis in Polish pediatric pneumonology units, including cystic fibrosis patients

Psychometric evaluation of the Nurses Observation Scale for Inpatient Evaluation in the Netherlands

Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients

Major Drug–Drug Interaction Exposure Among Medicaid-Insured Children in the Outpatient Setting

Evaluation of Potentially Inappropriate Prescription and Drug-Drug Interactions in the Critically Sick Elderly Patients in China

Prevalence of Potential Drug-Drug Interactions among Intensive Care Unit Patients Receiving Linezolid: a Cross-Sectional Study.

Evaluation of Clinical Impact of Pharmacogenomics Knowledge Involved in CPIC Guidelines on Chinese Pediatric Patients

Optimization of Cutting Process of Medium Density Fibreboards by the Abrasive Water-Jet

Identification of serious drug-drug interactions: Results of the partnership to prevent drug-drug interactions

Prevalence and comparative analysis of potential drug-drug interactions among hospitalized patients at a tertiary care cardiac institute in Pakistan: Findings from a single centre

Drug-induced kidney injury in Chinese critically ill pediatric patients

When Free 'Drug-Interaction Checker Mobile Apps' Ensure Interaction Free Medications for ICU Patients in Resource Limited Setups

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Prevalence and predictors of potential drug–drug interactions in patients of internal medicine wards of a tertiary care hospital in India

Epidemiology of potential drug- drug interactions in hospitalized patients with type 2 diabetes mellitus in China: a retrospective study

Drug Induced Liver Injury in Children: A Nationwide Cohort Study from China

DDInter: an online drug–drug interaction database towards improving clinical decision-making and patient safety

Potential drug-drug interactions and associated factors among hospitalized pediatric patients in Adigrat general hospital, Tigrai, north Ethiopia: a retrospective cross-sectional study

Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital